Opendata, web and dolomites

PREDICT SIGNED

Big Data EEG-Analysis for Advanced Personalised Medicine in Depression

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PREDICT project word cloud

Explore the words cloud of the PREDICT project. It provides you a very rough idea of what is the project "PREDICT" about.

suffer    depressive    invasive    metrics    percentage    trial    time    event    predicts    ranges    determines    fat    measured    patient    functions    remission    truly    hinders    equivalent    diagnosis    unable    cholesterol    easily    rarely    day    mental    tool    countless    tms    predict    personalised    quantifying    savings    dramatically    quality    gdp    mdd    weight    right    health    brain    treatment    brains    eluded       medicine    life    accurately    doctors    accounting    prescribed    body    98    antidepressants    equal    patients    disorders       temperature    compare    measuring    population    slows    modern    amelioration    responsiveness    therapies    heavy    costly    33    biomarkers    symptoms    52    treat    healthcare    total    rates    electroencephalogram    suspected    psa    ailments    error    delays    receiving    organ    diagnose    normal    disorder    validated    treatments    people    prevents    individual    improves    reduces    million    substantiation    ownership    elminda   

Project "PREDICT" data sheet

The following table provides information about the project.

Coordinator
ELMINDA LTD 

Organization address
address: Shenkar 1, WeWork Building
city: HERZLIYA
postcode: 4673314
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙798˙450 €
 EC max contribution 1˙958˙915 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELMINDA LTD IL (HERZLIYA) coordinator 1˙958˙915.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily compared against well-established normal ranges. And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us. Being unable to accurately measure and compare how a brain functions hinders doctors’ ability to diagnose and treat suspected ailments. It also slows the substantiation of new therapies. And, just as importantly, it prevents each of us from truly understanding and taking ownership of the health of our body’s most important organ. Major Depressive Disorder (MDD) has been identified as the leading and most costly mental disorder, accounting for 33% of the total cost of brain disorders, and equal to 1% of the GDP. Each year, about 7% of the population suffer from MDD in Europe, equivalent to 52.98 million people. The current methods of treatment are prescribed through trial and error with patients rarely receiving the ‘right’ treatment from day one. This reduces response rates and delays remission, which has a heavy impact on the individual’s quality of life. elminda has developed the “PREDICT” tool which predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms for MDD patients. PREDICT determines personalised treatments for MDD patients based on validated electroencephalogram and event-related potential brain-related biomarkers. The tool predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms. This improves response rates, quality of life and results in significant savings for the healthcare systems.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

B2BMarketplace (2019)

The first B2B marketplace for Fast Moving Consumer Goods, connecting all brand manufacturers and retailers globally

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More